Skip to main content
SpringerLink
Log in

Protein production by osteoblasts: modulation by breast cancer cell-derived factors

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Breast cancer cells (BCC) frequently metastasize to bone where they may cause tumor-induced osteolysis (TIO). While the important eroding role of the osteoclasts in TIO is well admitted, the possibility that BCC and/or osteoblasts activated by tumoral factors could also directly degrade bone matrix in this pathology has been much less investigated. We show here that the net collagen amount produced in vitro by normal human osteoblasts and osteoblast-like cells was significantly reduced by culture medium conditioned by several BCC lines, including three newly isolated ones. There was no evidence for a decrease in collagen synthesis, as assessed by the production of the carboxyterminal propeptide of type I collagen. In contrast, the effect of BCC-derived medium on collagen amount was attenuated by inhibitors of matrix metalloproteinases (MMPs) as well as by tranexamic acid, an inhibitor of the plasminogen conversion to plasmin, while it was abolished in presence of the two kinds of proteinase inhibitors. This osteoblastic protein degradation activity appeared to be attributable to factors secreted by the osteoblasts as well as by BCC. These factors had molecular weights lower as well as higher than 10 kD. Our data suggest that besides the eroding action of osteoclasts, BCC- and osteoblast-derived MMPs and serine proteinases might play a direct role in bone collagen degradation in TIO.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA., Kyle RA, Mundy GR, Paterson AHG, Rubens RD, for the International Bone and Cancer Study Group: Current use of bisphosphonates in oncology. J Clin Oncol 16: 3890–3899, 1998

    PubMed  Google Scholar 

  2. Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA: Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 15: 161–166, 1994

    PubMed  Google Scholar 

  3. Eilon G, Mundy GR: Direct resorption of bone by human breast cancer cells in vitro. Nature 276: 726–728, 1978

    PubMed  Google Scholar 

  4. Holiday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL: Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 272: 22053–22058, 1997

    PubMed  Google Scholar 

  5. Brown PD: Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 35: 293–301, 1995

    PubMed  Google Scholar 

  6. Hewson AK, Smith T, Leonard JP, Cuzner ML: Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 44: 345–349, 1995

    PubMed  Google Scholar 

  7. Siwek B, Larsimont D, Lacroix M, Body JJ: Establishment and characterization of three new breast-cancer cell lines. Int J Cancer 76: 677–683, 1998

    Google Scholar 

  8. Marie PJ, Lomri A, Sabbagh A, Basle M: Culture and behaviour of osteoblastic cells isolated from normal trabecular bone surfaces. In Vitro Dev Biol 25: 373–380, 1989

    Google Scholar 

  9. Peterkofsky B, Diegelmann R: Use of a mixture of proteinasefree collagenases for the specific assay of radioactive collagen in the presence of other proteins. Biochemistry 10: 988–994, 1971

    PubMed  Google Scholar 

  10. Melkko J, Niemi S, Risteli L, Risteli J: Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36: 1328–1332, 1990

    PubMed  Google Scholar 

  11. Lacroix M, Siwek B, Body JJ: Breast cancer response to calcitonin: modulation by growth-regulating agents. Eur J Pharmacol 344: 279–286, 1998

    PubMed  Google Scholar 

  12. Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22, 1997

    PubMed  Google Scholar 

  13. Stonelake PS, Jones CE, Neoptolemos JP, Baker PR: Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines. Br J Cancer 75: 951–959, 1997

    PubMed  Google Scholar 

  14. Johnson MD, Jeffrey AT, Lippman ME, Dickson RB: The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 53: 873–877, 1993

    PubMed  Google Scholar 

  15. Lacroix M, Siwek B, Body JJ: Effects of secretory products of breast cancer cells on osteoblast-like cells. Breast Cancer Res Treat 38: 209–216, 1996

    PubMed  Google Scholar 

  16. Siwek B, Lacroix M, De Pollak C, Marie P, Body JJ: Secretory products of breast cancer specifically affect human osteoblastic cells: partial characterization of active factors. J Bone Miner Res 12: 552–560, 1997

    PubMed  Google Scholar 

  17. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP: Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274: 13066–13076, 1999

    PubMed  Google Scholar 

  18. Silver IA, Murrills RJ, Etherington DJ: Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res 175: 266–276, 1988

    PubMed  Google Scholar 

  19. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56: 2815–2822, 1996

    PubMed  Google Scholar 

  20. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546–1550, 1995

    PubMed  Google Scholar 

  21. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149: 273–282, 1996

    PubMed  Google Scholar 

  22. Nutt JE, Lunec J: Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells. Eur J Cancer 32A: 2127–2135, 1996

    PubMed  Google Scholar 

  23. Rifas L, Fausto A, Scott MJ, Avioli LV, Welgus HG: Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase synthesis. Endocrinology 134: 213–221, 1994

    PubMed  Google Scholar 

  24. Freije JP, Diez-Itza I, Balbín M, Sánchez LM, Blasco R, Tolivia J, López-Otín C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269: 16766–16773, 1994

    PubMed  Google Scholar 

  25. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J: The new collagenase, collagenase-3 is expressed and synthesized by human chondrocytes but not by synoviocytes. J Clin Invest 97: 761–768, 1996

    PubMed  Google Scholar 

  26. Aimes RT, Quigley JP: Matrix metalloproteinase-2 is an interstitial collagenase. J Biol Chem 270: 5872–5876, 1995

    PubMed  Google Scholar 

  27. Cockett MI, Murphy G, Birch ML, O'Connell JP, Crabbe T, Millican AT, Hart IR, Docherty AJ: Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 63: 295–313, 1998

    PubMed  Google Scholar 

  28. Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G: Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 271: 17124–17131, 1996

    PubMed  Google Scholar 

  29. Lacroix M, Siwek B, Marie PJ, Body JJ: Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett 127: 29–35, 1998

    PubMed  Google Scholar 

  30. Hill PA, Tumber A, Papaioannou S, Meikle MC: The cellular actions of interleukin-11 on bone resorption in vitro. Endocrinology 139: 1564–1572, 1998

    PubMed  Google Scholar 

  31. Schrey MP, Patel KV: Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72: 1412–1419, 1995

    PubMed  Google Scholar 

  32. Sotiriou C, Lacroix M, Lagneaux L, Berchem G, Body JJ: The aspirine metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and-11. Anticancer Res 19: 2997–3006, 1999

    PubMed  Google Scholar 

  33. Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T: Regulation of matrix metalloproteinases (MMP-2,-3,-9, and-13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 139: 1338–1345, 1998

    PubMed  Google Scholar 

Download references

Authors
  1. Marc Lacroix
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre J. Marie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Jacques Body
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lacroix, M., Marie, P.J. & Body, JJ. Protein production by osteoblasts: modulation by breast cancer cell-derived factors. Breast Cancer Res Treat 61, 59–67 (2000). https://doi.org/10.1023/A:1006408916224

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006408916224

Search

Navigation